The FDA approved the Tecnis Eyhance and Tecnis Eyhance toric II IOLs for the treatment of patients with cataract, according to a press release.
The monofocal IOLs offer extended depth of focus, better image contrast in low-light environments and a new delivery system, protecting against contamination and streamlining delivery, the release said.
“Built on the proven Tecnis platform, Tecnis Eyhance combines low-light performance with breakthrough refractive surface design, providing a new kind of monofocal experience for cataract patients,” Rajesh K. Rajpal, MD, chief medical officer
Uncategorized